The combination of TH-302, a hypoxia-activated prodrug that reverses hypoxia, with PD-1 and CTLA-4 inhibitors may improve survival in mouse tumours as compared to TH-302 alone or dual antibody alone. Here, CTLA4 is linked to neoplasm.